The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer.
 
Heinz-Josef Lenz
Honoraria - Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Isofol Medical; Isofol Medical; Isofol Medical; Isofol Medical; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Merck Serono; Merck Serono; Merck Serono; Merck Serono
 
Peter Gibbs
Honoraria - Amgen; Amgen; Amgen; Amgen; Merck; Merck; Merck; Merck; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Ventana Medical Systems (Inst); Ventana Medical Systems (Inst); Ventana Medical Systems (Inst); Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - Servier; Servier; Servier; Servier
 
Sebastian Stintzing
Honoraria - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Takeda; Takeda; Takeda; Takeda
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Takeda; Takeda; Takeda; Takeda
 
Gerald W. Prager
Honoraria - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
 
Peter Nygren
Stock and Other Ownership Interests - Oncopeptides; Oncopeptides; Oncopeptides; Oncopeptides; Repos Pharma AB; Repos Pharma AB; Repos Pharma AB; Repos Pharma AB
Patents, Royalties, Other Intellectual Property - Repos Pharma AB; Repos Pharma AB; Repos Pharma AB; Repos Pharma AB
 
Christos A. Papadimitriou
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Genesis Pharmaceuticals; Genesis Pharmaceuticals; Genesis Pharmaceuticals; Genesis Pharmaceuticals; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche
 
Roger Tell
Employment - Aprea Therapeutics; Aprea Therapeutics; Aprea Therapeutics; Aprea Therapeutics; Isofol Medical; Isofol Medical; Isofol Medical; Isofol Medical
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)
 
Derek J. Jonker
No Relationships to Disclose
 
Aimery De Gramont
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BeiGene; BeiGene; BeiGene; BeiGene; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Genmab; Genmab; Genmab; Genmab; HalioDx; HalioDx; HalioDx; HalioDx; Halozyme; Halozyme; Halozyme; Halozyme; Imugene; Imugene; Imugene; Imugene; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Ipsen; Ipsen; Ipsen; Ipsen; Kura Oncology; Kura Oncology; Kura Oncology; Kura Oncology; Lilly; Lilly; Lilly; Lilly; Menarini; Menarini; Menarini; Menarini; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merrimack; Merrimack; Merrimack; Merrimack; Merus; Merus; Merus; Merus; Molecular Partners; Molecular Partners; Molecular Partners; Molecular Partners; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Peptomyc; Peptomyc; Peptomyc; Peptomyc; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; ProteoDesign; ProteoDesign; ProteoDesign; ProteoDesign; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Servier; Servier; Servier; Servier; Symphogen; Symphogen; Symphogen; Symphogen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; VCN Biosciences; VCN Biosciences; VCN Biosciences; VCN Biosciences